AIM ImmunoTech Reports $3M Net Loss and 37.5% Revenue Increase for Q1 2026

AIM ImmunoTech Inc. reported a net loss of $3.0 million for the three months ended March 31, 2026, a decrease of $682,000 compared to a net loss of $3.7 million during the same period in 2025. The company's total revenues increased by 37.5% to $22,000, driven primarily by clinical treatment programs in the U.S. Total costs and expenses fell to $2.2 million, down from $3.6 million in the prior year, largely due to reduced research and development costs, which dropped by 55.4% to $482,000. This reduction reflects AIM's strategic decision to focus on the development of Ampligen for late-stage pancreatic cancer, leading to decreased spending on non-core patent maintenance.

In terms of operational developments, AIM's ongoing Phase 2 clinical trial for Ampligen in combination with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor, Imfinzi, is progressing, with 24 patients treated as of March 31, 2026. The company has also entered into a partnership with Thermo Fisher Scientific to design a Phase 3 clinical trial for Ampligen in treating late-stage pancreatic cancer. AIM's stockholder equity stood at $2.1 million as of March 31, 2026, which is below the NYSE American's minimum requirement of $6 million, raising concerns about the company's ability to maintain its listing.

AIM's cash and cash equivalents increased significantly to $5.8 million, up from $3.0 million at the end of 2025, primarily due to financing activities, including a rights offering that raised $1.8 million and proceeds from warrant exercises. However, cash used in operating activities rose to $2.7 million, reflecting ongoing operational costs. The company continues to face liquidity challenges, with substantial doubt regarding its ability to continue as a going concern over the next year unless it can secure additional funding.

Looking ahead, AIM ImmunoTech is focused on advancing its clinical trials and securing necessary capital to support its operations. The company is actively exploring various financing options, including equity offerings and potential partnerships, to bolster its financial position and meet the NYSE American's listing requirements. AIM's management remains optimistic about the potential of Ampligen in treating pancreatic cancer and other conditions, but acknowledges the uncertainties inherent in clinical trials and regulatory approvals.